A Randomized, Double-blind, Vehicle-Controlled Phase 2a Study Evaluating Once Daily Roflumilast Foam 0.3% in Patients With Moderate to Severe Seborrheic Dermatitis. J of Skin. 2021;5(6):s94. doi:10.25251/skin.5.supp.94